Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of tildrakizumab in psoriatic arthritis
jRCT2031220622Active, not recruiting
- Sponsor
- Sun Pharma
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of tildrakizumab in psoriatic arthritis (PsA), sponsored by Sun Pharma. Primary endpoints: Incidence and intensity of adverse events, Proportion of subjects achieving ACR20 response and 2 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
tildrakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT2031220622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220622.